



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 14, 2008 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:25**
 - No follow-up items
- 6. Clinical Update: Drug Reviews** **7:25 – 7:50**

(Public comment prior to Board action)

 - Arcalyst[®] (rilonacept) Vial for Subcutaneous Injection
 - Fenoglide[®] (fenofibrate) Tablet
 - Omnaris[®] (ciclesonide) Nasal Spray (abbreviated Nasal Corticosteroids class review)
 - Renvela[®] (sevelamer carbonate) Tablet (abbreviated Phosphate Binders class review)
 - Voltaren[®] (diclofenac sodium 1%) Topical Gel
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:50 – 8:35**

Specialty Pharmacy

 - Elaprase[®]
 - Growth Stimulating Agents
 - Hemophilia Factors
 - Hepatitis C (B) Medications
 - Multiple Sclerosis Injectables
 - Synagis[®]

Annual Review – No Changes Recommended

 - Acne Drugs: Oral
 - Acne Drugs: Topical - Anti-Infectives
 - Acne Drugs: Topical – Retinoids
 - Acne Drugs: Topical – Rosacea

Annual Review – No Changes Recommended continued

- Alzheimer's: Cholinesterase Inhibitors/NMDA Receptor Antagonists
- Anemia Medications: Hematopoietic/Erythropoietic Agents
- Anticoagulants
- Anti-Emetics: 5-HT₃ receptor Antagonists
- Anti-Emetics: Other
- Anti-Infectives: Macrolides
- Anti-Infectives: Miscellaneous
- Anti-Infectives: Oxazolidinones
- Glucocorticoids: Topical
- Pulmonary: Antihistamines- 1st Generation
- Pulmonary: Systemic Glucocorticoids
- Saliva Stimulants
- Vitamins: Prenatal Vitamins

8. Drug Classes – New **8:35 – 8:35**
▪ No new drug classes

9. RetroDUR **8:35 - 8:40**
▪ Lidoderm[®] (lidocaine 5%) Transdermal Patch

10. New Drug Product Plan Exclusions (Consent Agenda Topic) **8:40 - 8:45**

11. Updated New-to-Market Drug Monitoring Log **8:45 - 8:50**

12. General Announcements **8:50 - 9:00**

Selected FDA Safety Alerts

- Statin Drugs – no link with ALS
- Epoetin alfa – more deaths in study when used to treat acute ischemic stroke
- Tarceva[®] – hepatic failure
- Rituxan[®] – case of PML
- TNF blockers – opportunistic infections not recognized
- Spiriva[®] – increased risk for mortality and/or cardiovascular events

13. Adjourn **9:00**